Clinical Trials Directory

Trials / Conditions / ALK-positive NSCLC

ALK-positive NSCLC

8 registered clinical trials studyying ALK-positive NSCLC — 2 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497
TRIANA Biomedicines, Inc.Phase 1 / Phase 2
Not Yet RecruitingResistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCL
NCT06904547
Shanghai Chest Hospital—
UnknownA Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC
NCT05482087
Xuanzhu Biopharmaceutical Co., Ltd.Phase 2
CompletedReal-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and
NCT04647110
Pfizer—
UnknownStudy of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (A
NCT04009317
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
UnknownStudy of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC
NCT04056572
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2
UnknownThe Absorption, Metabolism and Excretion of [14C]Ensartinib in Human
NCT03804541
Betta Pharmaceuticals Co., Ltd.Phase 1
Active Not RecruitingStudy of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-smal
NCT02393625
Novartis PharmaceuticalsPhase 1